Skip to main content

Advertisement

SpringerLink
Log in

Biomarkers in overactive bladder

  • Review Article
  • Published:
International Urogynecology Journal Aims and scope Submit manuscript

An Erratum to this article was published on 01 August 2013

Abstract

A biomarker is an indicator of a particular disease. It is generally used to define the presence (diagnostic biomarker), severity, progression (prognostic biomarker) of a condition and/or its response to a specific treatment (predictive biomarker). Biomarkers can be specific cells, enzymes, hormones, genes or gene products, which can be detected and measured in parts of the body such as blood, urine or tissue. Therefore, biomarkers have been suggested to play an important role in both the clinical assessment and the management of patients, as well as in the research setting. Recently, interest has gathered in urinary biomarkers as a tool to assess overactive bladder (OAB), potentially playing a role in the diagnosis, disease progression and monitoring response to treatment. Urinary biomarkers identified so far include nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), prostaglandins, cytokines and C-reactive protein. The aim of this review was to review the published literature on biomarkers in OAB. A literature review using Pub Med, clinicaltrials.gov and the controlled trials online registries was performed from 1970 up to June 2012. The search keywords were: the International Continence Society (ICS) definition of "OAB", “nerve growth fac- tor” (NGF), “brain derived growth factor” (BDNF), “prostaglandins,” “cytokines,” “genetic biomarkers” and “C reactive protein”.

The results were limited for fully published English-language articles. The search was then subsequently expanded to include urinary biomarkers in interstitial cystitis and bladder pain where relevant. Each of the studies/articles was reviewed, interpreted and discussed to consider the role of urinary biomarkers in OAB. Using the search criteria, a total of 20 studies (animal and human) that investigated the role of urinary biomarkers in OAB were identified. Full text versions of these articles were obtained and reviewed. Studies on NGF suggested that urinary levels were higher in OAB patients and decreased with antimuscarinic and botulinum toxin treatment. BDNF studies have demonstrated raised levels in OAB and also increased levels in situations of acute bladder inflammation. The role of urinary prostaglandins, cytokines and CRP does not appear to be specific to the OAB disease process according to the current available evidence. Based on the evidence so far NGF and BDNF appear to be the most promising biomarkers in OAB. Although still in their infancy these neurotrophic factors could potentially diagnose OAB, replacing urodynamics and aiding in monitoring disease progression and response to treatment in addition to clinical symptoms.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Haylen BT, de Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J et al (2010) An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J Pelvic Floor Dysfunct 21(1):5–26. doi:10.1007/s00192-009-0976-9

  2. Cartwright R, Afshan I, Derpapas A, Vijaya G, Khullar V (2011) Novel biomarkers for overactive bladder. Nat Rev Urol Mar 8(3):139–145

    Article  CAS  Google Scholar 

  3. Chu FM, Dmochowski R (2006) Pathophysiology of overactive bladder. Am J Med 119 [3 Suppl 1]:3–8

    Article  PubMed  Google Scholar 

  4. Steers WD (2002) Pathophysiology of overactive bladder and urge urinary incontinence. Rev Urol 4 [Suppl 4]:S7–S18

    PubMed  Google Scholar 

  5. Tanner R, Chambers P, Khadra MH, Gillespie JI (2000) The production of nerve growth factor by human bladder smooth muscle cells in vivo and in vitro. BJU Int 85(9):1115–1119

    Article  PubMed  CAS  Google Scholar 

  6. Vizzard MA (2000) Changes in urinary bladder neurotrophic factor mRNA and NGF protein following urinary bladder dysfunction. Exp Neurol 161(1):273–284

    Article  PubMed  CAS  Google Scholar 

  7. Moore KH, Simons A, Mukerjee C, Lynch W (2000) The relative incidence of detrusor instability and bacterial cystitis detected on the urodynamic-test day. BJU Int 85(7):786–792

    Article  PubMed  CAS  Google Scholar 

  8. Hessdoerfer E, Jundt K, Peschers U (2011) Is a dipstick test sufficient to exclude urinary tract infection in women with overactive bladder? Int Urogynecol J 22(2):229–232

    Article  PubMed  Google Scholar 

  9. Walsh CA, Siddins A, Parkin K, Mukerjee C, Moore KH (2011) Prevalence of “low-count” bacteriuria in female urinary incontinence versus continent female controls: a cross-sectional study. Int Urogynecol J 22(10):1267–1272

    Article  PubMed  Google Scholar 

  10. Oddiah D, Anand P, McMahon SB, Rattray M (1998) Rapid increase of NGF, BDNF and NT-3 mRNAs in inflamed bladder. Neuroreport 9(7):1455–1458

    Article  PubMed  CAS  Google Scholar 

  11. Qiao LY, Vizzard MA (2002) Cystitis-induced upregulation of tyrosine kinase (TrkA, TrkB) receptor expression and phosphorylation in rat micturition pathways. J Comp Neurol 454(2):200–211

    Article  PubMed  CAS  Google Scholar 

  12. Kim JC, Park EY, Seo SI, Park YH, Hwang TK (2006) Nerve growth factor and prostaglandins in the urine of female patients with overactive bladder. J Urol 175(5):1773–1776

    Article  PubMed  CAS  Google Scholar 

  13. Liu HT, Chancellor MB, Kuo HC (2009) Decrease of urinary nerve growth factor levels after antimuscarinic therapy in patients with overactive bladder. BJU Int 103(12):1668–1672

    Article  PubMed  CAS  Google Scholar 

  14. Liu HT, Lin H, Kuo HC (2011) Increased serum nerve growth factor levels in patients with overactive bladder syndrome refractory to antimuscarinic therapy. Neurourol Urodyn 30(8):1525–1529

    Article  PubMed  Google Scholar 

  15. Liu HT, Chancellor MB, Kuo HC (2009) Urinary nerve growth factor levels are elevated in patients with detrusor overactivity and decreased in responders to detrusor botulinum toxin-A injection. Eur Urol 56(4):700–706

    Article  PubMed  CAS  Google Scholar 

  16. Kuo HC, Liu HT, Tyagi P, Chancellor MB (2010) Urinary nerve growth factor levels in urinary tract diseases with or without frequency urgency syndrome. LUTS 2:88–94

    CAS  Google Scholar 

  17. Merighi A, Salio C, Ghirri A, Lossi L, Ferrini F, Betelli C et al (2008) BDNF as a pain modulator. Prog Neurobiol 85(3):297–317

    Article  PubMed  CAS  Google Scholar 

  18. Michael GJ, Averill S, Nitkunan A, Rattray M, Bennett DL, Yan Q et al (1997) Nerve growth factor treatment increases brain-derived neurotrophic factor selectively in TrkA-expressing dorsal root ganglion cells and in their central terminations within the spinal cord. J Neurosci 17(21):8476–8490

    PubMed  CAS  Google Scholar 

  19. Pezet S, Malcangio M, McMahon SB (2002) BDNF: a neuromodulator in nociceptive pathways? Brain Res Brain Res Rev 40(1–3):240–249

    Article  PubMed  CAS  Google Scholar 

  20. Pinto R, Frias B, Allen S, Dawbarn D, McMahon SB, Cruz F et al (2010) Sequestration of brain derived nerve factor by intravenous delivery of TrkB-Ig2 reduces bladder overactivity and noxious input in animals with chronic cystitis. Neuroscience 166(3):907–916

    Article  PubMed  CAS  Google Scholar 

  21. Pinto R, Lopes T, Frias B, Silva A, Silva JA, Silva CM et al (2010) Trigonal injection of botulinum toxin A in patients with refractory bladder pain syndrome/interstitial cystitis. Eur Urol Sep 58(3):360–365

    Article  CAS  Google Scholar 

  22. Antunes-Lopes T, Pinto R, Carvalho-Barros S, Diniz P, Martins-Silva C et al (2012) Urinary levels of brain derived neurotrophic factor (BDNF) in women with overactive bladder (OAB) syndrome correlate with the severity of symptoms. Eur Urol Suppl 10(2):277–278

    Article  Google Scholar 

  23. Bultitude MI, Hills NH, Shuttleworth KE (1976) Clinical and experimental studies on the action of prostaglandins and their synthesis inhibitors on detrusor muscle in vitro and in vivo. Br J Urol 48(7):631–637

    Article  PubMed  CAS  Google Scholar 

  24. Ishizuka O, Mattiasson A, Andersson KE (1995) Prostaglandin E2-induced bladder hyperactivity in normal, conscious rats: involvement of tachykinins. J Urol 153(6):2034–2038

    Article  PubMed  CAS  Google Scholar 

  25. Schussler B (1990) Comparison of the mode of action of prostaglandin E2 (PGE2) and sulprostone, a PGE2-derivative, on the lower urinary tract in healthy women. A urodynamic study. Urol Res 18:349–352

    Article  PubMed  CAS  Google Scholar 

  26. Liu HT, Tyagi P, Chancellor MB, Kuo HC (2010) Urinary nerve growth factor but not prostaglandin E2 increases in patients with interstitial cystitis/bladder pain syndrome and detrusor overactivity. BJU Int 106(11):1681–1685

    Article  PubMed  Google Scholar 

  27. Tyagi P, Barclay D, Zamora R, Yoshimura N, Peters K, Vodovotz Y et al (2010) Urine cytokines suggest an inflammatory response in the overactive bladder: a pilot study. Int Urol Nephrol 42(3):629–635

    Article  PubMed  Google Scholar 

  28. Ghoniem G, Faruqui N, Elmissiry M, Mahdy A, Abdelwahab H, Oommen M et al (2011) Differential profile analysis of urinary cytokines in patients with overactive bladder. Int Urogynecol J 22(8):953–961

    Article  PubMed  Google Scholar 

  29. Kushner I (1982) The phenomenon of the acute phase response. Ann N Y Acad Sci 389:39–48

    Article  PubMed  CAS  Google Scholar 

  30. Pepys MB, Hirschfield GM (2003) C-reactive protein: a critical update. J Clin Invest 111(12):1805–1812

    PubMed  CAS  Google Scholar 

  31. Hsiao SM, Lin HH, Kuo HC (2012) The role of serum C-reactive protein in women with lower urinary tract symptoms. Int Urogynecol J 23(7):935-940 doi:10.1007/s00192-012-1715-1

    Article  PubMed  Google Scholar 

  32. Chuang YC, Tyagi V, Liu RT, Chancellor MB, Tyagi P (2010) Urine and serum C-reactive protein levels as potential biomarkers of lower urinary tract symptoms. Urol Sci 21(3):132–136

    Article  CAS  Google Scholar 

  33. Chung SD, Liu HT, Lin H, Kuo HC (2011) Elevation of serum c-reactive protein in patients with OAB and IC/BPS implies chronic inflammation in the urinary bladder. Neurourol Urodyn 30(3):417–420

    Article  PubMed  CAS  Google Scholar 

  34. Kupelian V, McVary KT, Barry MJ, Link CL, Rosen RC, Aiyer LP et al (2009) Association of C-reactive protein and lower urinary tract symptoms in men and women: results from Boston Area Community Health survey. Urology 73(5):950–957

    Article  PubMed  Google Scholar 

  35. Van der Hel OL, van der Luijt RB, Bueno de Mesquita HB, van Noord PA, Slothouber B, Roest M et al (2002) Quality and quantity of DNA isolated from frozen urine in population-based research. Anal Biochem 304(2):206–211

    Google Scholar 

  36. Wennberg A-L, Altman D, Lundholm C, Klint A, Iliadou A, Peeker R et al (2011) Genetic influences are important for most but not all lower urinary tract symptoms: a population-based survey in a cohort of adult Swedish twins. Eur Urol 59(6):1032–1038

    Article  PubMed  Google Scholar 

  37. Rohr G, Kragstrup J, Gaist D, Christensen K (2004) Genetic and environmental influences on urinary incontinence: a Danish population-based twin study of middle-aged and elderly women. Acta Obstet Gynecol Scand 83(10):978–982

    PubMed  Google Scholar 

  38. Ferreira CE, Fonseca AM, Silva ID, Girão MJ, Sartori MG, Castro RA (2011) The relationship between the Trp 64 Arg polymorphism of the beta 3-adrenoceptor gene and idiopathic overactive bladder. Am J Obstet Gynecol 205(1):82.e10–4

    Article  Google Scholar 

Download references

Conflicts of interest

None.

Author information

Authors and Affiliations

  1. Department of Urogynaecology, St. Mary’s Hospital, Cambridge Wing, Praed Street, W1 1NY, London, UK

    Alka A. Bhide, Rufus Cartwright, Vik Khullar & G. Alessandro Digesu

Authors
  1. Alka A. Bhide
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rufus Cartwright
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Vik Khullar
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G. Alessandro Digesu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G. Alessandro Digesu.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bhide, A.A., Cartwright, R., Khullar, V. et al. Biomarkers in overactive bladder. Int Urogynecol J 24, 1065–1072 (2013). https://doi.org/10.1007/s00192-012-2027-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00192-012-2027-1

Keywords

Search

Navigation